Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin

Phase 3TerminatedNCT01136746

Eli Lilly and Company16 enrolled

Overview

The purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes.

This study involves a comparison of 2 methods for administering subcutaneous insulin therapy to non-critically ill adult patients with hyperglycemia and without known history of diabetes who are admitted to non-intensive care unit (ICU) general medical hospital services. Basal-bolus therapy, considered the gold standard for glucose control in patients with known diabetes, will be compared with sliding scale insulin, a commonly used method of glucose control (prevailing standard practice) in hospitalized patients. In this study, basal-bolus therapy will consist of once-daily glargine plus lispro 3 to 4 times daily adjusted to achieve pre-meal capillary plasma glucose \<140 milligrams per deciliter (mg/dL) and bedtime capillary plasma glucose \<180 mg/dL for patients who are eating \[predose plasma glucose \<140 mg/dL for patients with nil per os (NPO) orders\]; sliding scale insulin will be administered using human regular insulin 4 times daily as needed adjusted to achieve predose capillary plasma glucose target \<140 mg/dL in patients who are eating or have NPO orders.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hyperglycemia

Interventions

Human regular insulinDRUG

Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)

Insulin lisproDRUG

Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)

Insulin glargineDRUG

Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Major Inclusion Criteria: * No known history of diabetes * Admission or pre-entry plasma glucose (PG) level between 140 and 400 mg/dL * Non-critically ill and admitted to acute care medical services * Have a body mass index greater than or equal to 18.5 kg/m\^2 and less than or equal to 45 kilograms per square meter (kg/m\^2) Major Exclusion Criteria: * Received any insulin/analog therapy for longer than 108 hours prior to study entry or intermediate- or long-acting insulin/analogs (neutral protamine Hagedorn, detemir, or glargine) in the 24 hours prior to randomization or any intravenous insulin therapy prior to randomization * Laboratory evidence of diabetic ketoacidosis for patients with pre-randomization PG greater than 250 mg/dL * Have taken any oral or injectable antihyperglycemic medications other than insulin within 3 months prior to study entry * Have acute critical illness or are expected to require admission to an ICU or equivalent or be treated with glucocorticoid therapy during the hospital study period * Expected hospitalization less than 24 hours post-randomization

Locations (12)

Outcomes

Primary Outcomes

Mean Plasma Glucose (MPG) Throughout Hospital Study Period

Overall MPG is derived as the mean of plasma glucose (PG) readings from Day/Visit 1 to Day/Visit 10.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period

Results are reported as the percentage of total number of capillary plasma glucose measurements within the range of 71 to 179 mg/dL for each treatment arm.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Secondary Outcomes

Mean Plasma Glucose (MPG) by Hospital Day

The intent was to report results up to Day 10; however, due to low enrollment, mean and standard deviations are only reported up to Day 7.

Time frame: Day 1 up to day 7 of hospital study period

Percentage of Plasma Glucose Measurements Within Range 71 to 179 mg/dL by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Day 1 up to day 10 of hospital study period

Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL Throughout Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Birmingham, Alabama, United States

Jacksonville, Florida, United States

Miami, Florida, United States

Weston, Florida, United States

Atlanta, Georgia, United States

Topeka, Kansas, United States

Hazard, Kentucky, United States

Bangor, Maine, United States

Kansas City, Missouri, United States

Cleveland, Ohio, United States

...and 2 more locations

Time frame: Day 1 up to day 10 of hospital study period

Mean Fasting Plasma Glucose (FPG) by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Day 1 up to day 10 of hospital study period

Mean FPG Throughout Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Day 1 up to day 10 of hospital study period

Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Day 1 up to day 10 of hospital study period

Percentage of Capillary PG Measurements >240 mg/dL Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

Percentage of Capillary PG Measurements >240 mg/dL by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Day 1 up to day 10 of hospital study period

Total Daily Dose (TDD) of Insulin (Units) Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

TDD of Insulin (Units/kg) Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

TDD of Insulin (Units) by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Day 1 up to day 10 of hospital study period

TDD of Insulin (Units/kg) by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Day 1 up to day 10 of hospital study period

Length of Hospital Stay Post-randomization Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, Throughout Hospital Study Period

Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL (Umpierrez et al. 2007; Moghissi et al. 2009; Umpierrez et al. 2009), even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), Throughout Hospital Study Period

Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, by Hospital Day

Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.

Time frame: Day 1 up to day 10 of hospital study period

Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), by Hospital Day

Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.

Time frame: Day 1 up to day 10 of hospital study period

Number of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period

Treatment-emergent adverse event - any untoward medical occurrence that either occurred or worsened at any time after treatment baseline and which did not necessarily have a causal relationship with this treatment. A summary of adverse events is located in the Reported Adverse Event Module.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Percentage of Participants Requiring Intensive Care Unit Transfer

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Percentage of Participants With Deterioration of Renal Function Throughout the Hospital Study Period

Deterioration of renal function was defined by an increase in serum creatinine by \>0.5 milligrams per deciliter (mg/dL). Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Percentage of Participants With Documented Nosocomial Infections

Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Number of Participants With Major Adverse Cardiovascular Events (MACE)

MACE was defined as the composite of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke. Due to low enrollment, this outcome measure was not analyzed.

Time frame: Throughout hospital study period (1 to 10 days post-randomization)